Samuel Waksal is the founder of Graviton. Graviton has raised $65M in total funding. Latest round: Series A. Based in New York, New York.
Samuel Waksal is the founder and chief executive officer of Graviton Bioscience, a privately held clinical-stage biotechnology company focused on developing selective ROCK2 inhibitors for serious diseases. He has also founded ImClone Systems, Kadmon Biopharmaceuticals, and MeiraGTx.
Full founder directory · Investor directory · Company funding database · Fundraising library